false
0001792941
0001792941
2026-04-16
2026-04-16
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or
15(d) of the Securities Exchange Act of 1934
Date of Report: April
16, 2026
GENVOR INCORPORATED
(Exact name of Registrant
as specified in its Charter)
| Nevada |
000-56589 |
83-2054746 |
| (State or Other Jurisdiction of |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
| Incorporation) |
|
|
1550 W Horizon Ridge Pkwy,
Ste R #3040
Henderson, NV 89012
(Address of Principal Executive
Offices)
(715) 903-6473
(Registrant’s Telephone
Number, including area code)
N/A
(Former name or former address,
if changed since last report)
Check the appropriate box
below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following
provisions (see general instruction A.2. below):
☐ Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting
material pursuant to Rule 14-a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b)
of the Act: None.
| Title of each class |
|
Trading Symbols(s) |
|
Name of each exchange on which registered |
| N/A |
|
N/A |
|
N/A |
Indicate by check mark whether the registrant is an
emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter). ☒
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 1.01. Entry into a Material Definitive Agreement.
Effective April 16, 2026, Genvor Incorporated (the
“Company”) entered into a securities purchase agreement (the “SPA”) with Evergreen Capital Management
LLC (“Evergreen”), pursuant to which the Company sold, and Evergreen purchased, (i) a convertible promissory note in
the aggregate principal amount of up to $800,000 (the “Note”), and (ii) warrants to purchase up to 600,000 shares of
Company common stock (the “Warrants”), for an aggregate purchase price of up to $666,668 (the “Purchase Price”).
The Purchase Price is to be paid in four tranches of $166,667 (each, a “Tranche”), with the first Tranche paid at the
initial closing of the transaction, and the remaining three Tranches paid to the Company upon (i) the Company’s filing of a registration
statement on Form S-1 registering for resale shares of Company common stock issuable upon conversion of the Note, and (ii) receiving comments
from the United States Securities and Exchange Commission on that registration statement. Evergreen shall retain $10,000 from each Tranche
to cover its legal fees and closing costs. The first Tranche was funded on April 16, 2026, and on that date, the Note and Warrants were
issued to Evergreen.
The SPA includes customary representations, warranties
and covenants by the Company and customary closing conditions. For each Tranche funded under the Note to the Company, the Note principal
shall consist of $200,000 (up to an aggregate of $800,000 if all four Tranches are funded to the Company). The Note matures upon the earlier
of (i) 9 months following the Issue Date set forth in the Note (April 15, 2026), or (ii) the listing of the Company’s common stock
on a national securities exchange (an “Exchange Listing”), such as the Nasdaq Capital Market. The Note accrues interest
at 10% per annum and is convertible into shares of the Company’s common stock at $1.00 per share, or 80% of the lowest volume-weighted
average price during the 5 trading days preceding conversion upon the occurrence of any event of default; provided, however, that the
holder may not convert the Note to the extent that such conversion would result in the holder’s beneficial ownership of the Company’s
common stock being in excess of 4.99% of the Company’s issued and outstanding common stock. The Warrants only entitle the holder
to purchase up to 300,000 shares initially, and upon the funding of the second Tranche under the Note, entitle the holder to purchase
up to an additional 300,000 shares. The Warrants have a 5-year term, are exercisable on a cashless basis, and have an initial exercise
price of $1.00, subject to adjustment so that the exercise price under the Warrants equals the applicable conversion price under the Note.
On April 16, 2026, the Company also entered into an
Advisory Agreement (the “Advisory Agreement”) with Brio Advisory Group (the “Consultant”), pursuant
to which the Consultant will provide the Company advisory services in connection with strategic initiatives, capitalization, financial
and other planning, due diligence, financing efforts, and an Exchange Listing, and the Company will issue to the Consultant shares of
preferred stock which will be valued as follows: (i) $300,000 per Tranche ($1,200,000 in the aggregate if all four Tranches of funding
under the Note are funded to the Company) at the time of the Exchange Listing, or (ii) if there is no Exchange Listing within one year
of the date of the Advisory Agreement, that will convert into $300,000 of Company common stock per Tranche based on the 5-day average
closing price at such time, but in no event at less than $1.00 per share.
The foregoing descriptions of the SPA, Note, Warrants,
and Advisory Agreement do not purport to be complete and are qualified in their entirety by reference to the full text of those agreements,
copies of which are filed as Exhibits 10.1-10.4, respectively, to this Current Report on Form 8-K and incorporated by reference herein.
| Item 9.01 | Financial Statements and Exhibits. |
(d) Exhibits
| Exhibit No. |
|
Description |
| |
|
|
| 10.1 |
|
Securities Purchase Agreement, dated April 15, 2026, between the Company and Evergreen Capital Management LLC * |
| |
|
|
| 10.2 |
|
Convertible Promissory Note, dated April 21, 2026, by the Company to Evergreen Capital Management LLC * |
| |
|
|
| 10.3 |
|
Common Share Purchase Warrant, dated April 15, 2026, by the Company to Evergreen Capital Management LLC * |
| |
|
|
| 10.4 |
|
Advisory Agreement, dated April 14, 2026, between the Company and Brio Advisory Group LLC * |
| |
|
|
| 104 |
|
Cover Page Interactive Data File (embedded within the Inline XBRL Document) |
* Filed herewith.
SIGNATURES
Pursuant to the requirements of the Securities Exchange
Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Date: April 22, 2026
| |
GENVOR INCORPORATED |
| |
|
| |
By: /s/ Chad Pawlak
Name: Chad Pawlak
Title: Chief Executive Officer |